【0】Manidipine: International drug information (concise)

【1】Contributor Disclosures

【2】For abbreviations, symbols, and age group definitions show table

【3】International Brand Names

【4】International Brand Names by Country

【5】For country code abbreviations ( show table )  

*   (BR) Brazil : Dicloridrato de manidipino | Manivasc ;
*   (CN) China : Manidipine dihydrochloride | Shu ping xi ;
*   (DE) Germany : Manyper ;
*   (ES) Spain : Artedil | Manidipino Cinfa | Manidipino combix | Manidipino Kern | Manidipino mylan | Manidipino Normon | Manidipino Ratiopharm | Manidipino Sandoz | Manidipino stada | Manidipino Teva | Manidipino vir ;
*   (FR) France : Iperten | Manidipine biogaran | Manidipine Dci | Manidipine eg | Manidipine Mylan | Manidipine sandoz | Manidipine Teva | Manidipine Zentiva | Manidipine zydus ;
*   (GR) Greece : Manyper | Presidin ;
*   (IT) Italy : Erreman | Iperten | Manidipina | Manidipina Chiesi | Manidipina EG | Manidipina Fidia | Manidipina Sandoz | Manidipina Teva | Vascoman ;
*   (JP) Japan : Bilosbit | Calet | Calslot | Calvadine | Canselin | Jimrost | Kaoltone | Manicalot | Manidilot | Manidilot hexal | Manidip ;
*   (KR) Korea, Republic of : Madipine ;
*   (PH) Philippines : Caldine | Minadil ;
*   (TH) Thailand : Cardiplot | Kerdica | Madiplot | Nikp manidipine ;
*   (TN) Tunisia : Iperten ;
*   (TR) Turkey : Iperten

【7】Index Terms

【8】*   Manidipine Dihydrochloride;
*   Manidipine Hydrochloride

【9】Pharmacologic Category

【10】*   Antihypertensive ;
*   Calcium Channel Blocker ;
*   Calcium Channel Blocker, Dihydropyridine

【11】Reported Use

【12】Management of hypertension

【13】Dosage Range

【14】Adults: Oral: Initial: 5 mg to 10 mg once daily; may increase to 20 mg once daily based on response and tolerability

【15】Product Availability

【16】Product available in various countries; not currently available in the US

【17】Dosage Forms

【18】Tablet, as hydrochloride: 5 mg, 10, mg, 20 mg; as dihydrochloride: 10 mg, 20 mg

【19】Topic 10409 Version 53.0黄艳玲

====================================================================================================
